Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-Risk Hematologic Malignancies
Orly R. Klein(Sidney Kimmel Comprehensive Cancer Center), Heather J. Symons(Johns Hopkins University), Leo Luznik(Sidney Kimmel Comprehensive Cancer Center), Mary Jo Holuba(Johns Hopkins Hospital), David M. Loeb(Albert Einstein College of Medicine), Jeffrey S. Huo, Richard J. Jones(Sidney Kimmel Cancer Center), Christopher Gamper(Johns Hopkins University), Nancy Robey(Johns Hopkins Hospital), Kenneth R. Cooke(Sidney Kimmel Comprehensive Cancer Center), Nicolás J. Llosa(Sidney Kimmel Comprehensive Cancer Center), Jessica Buddenbaum(Johns Hopkins University), Yvette L. Kasamon(Johns Hopkins University), Ephraim J. Fuchs(Johns Hopkins Hospital), Shannon R. McCurdy(Johns Hopkins Hospital), Richard F. Ambinder(Johns Hopkins University), Noah Tucker(Johns Hopkins University), Elias T. Zambidis(University of Maryland, Baltimore), Allen Chen(Johns Hopkins University), Javier Bolaños‐Meade(Johns Hopkins University)
Cited by 73
Related Papers
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k
The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
|Cancer Discovery|2014|1.5k
Hepatic Veno-Occlusive Disease following Stem Cell Transplantation: Incidence, Clinical Course, and Outcome
|Biology of Blood and Marrow Transplantation|2009|595
B Cells Turn Off Virgin But Not Memory T Cells
|Science|1992|570